BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 23419459)

  • 1. Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study.
    Schulte-Baukloh H; Priefert J; Knispel HH; Lawrence GW; Miller K; Neuhaus J
    Urology; 2013 May; 81(5):1052-7. PubMed ID: 23419459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC; Kuo HC
    Neurourol Urodyn; 2014 Jan; 33(1):129-34. PubMed ID: 23494629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics.
    Kuo HC
    Neurourol Urodyn; 2011 Sep; 30(7):1242-8. PubMed ID: 21560152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ba-Wei-Die-Huang-Wan (Hachimi-jio-gan) can ameliorate cyclophosphamide-induced ongoing bladder overactivity and acidic adenosine triphosphate solution-induced hyperactivity on rats prestimulated bladder.
    Lee WC; Wu CC; Chuang YC; Tain YL; Chiang PH
    J Ethnopharmacol; 2016 May; 184():1-9. PubMed ID: 26719284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D; Gousse A; Keppenne V; Sievert KD; Thompson C; Lam W; Brin MF; Jenkins B; Haag-Molkenteller C
    J Urol; 2012 Jun; 187(6):2131-9. PubMed ID: 22503020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury.
    Chen SF; Jiang YH; Kuo HC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):125-133. PubMed ID: 29482913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
    Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S
    Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of M2 and M3 muscarinic receptor expression in bladder from women with refractory idiopathic detrusor overactivity.
    Mansfield KJ; Liu L; Moore KH; Vaux KJ; Millard RJ; Burcher E
    BJU Int; 2007 Jun; 99(6):1433-8. PubMed ID: 17428242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
    Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
    Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual receptor profiling as a novel tool to support diagnosis of bladder pain syndrome/interstitial cystitis (BPS/IC).
    Neuhaus J; Schulte-Baukloh H; Stolzenburg JU; Speroni di Fenizio P; Horn LC; Rüffert H; Hartenstein S; Burger M; Schulze M; Schwalenberg T
    World J Urol; 2012 Oct; 30(5):693-700. PubMed ID: 21969132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.
    Apostolidis A; Popat R; Yiangou Y; Cockayne D; Ford AP; Davis JB; Dasgupta P; Fowler CJ; Anand P
    J Urol; 2005 Sep; 174(3):977-82; discussion 982-3. PubMed ID: 16094018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses.
    Grise P; Ruffion A; Denys P; Egon G; Chartier Kastler E
    Eur Urol; 2010 Nov; 58(5):759-66. PubMed ID: 20674149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.